AQAI Simulation Centre Mayence optimises training in use of anaesthetics
24 September 2012
Medical products supplier Baxter is co-operating with the AQAI Simulation Centre
to train new customers' medical and nursing staff in the Middle East
to use its anaesthetic quickly and without risk for patients.
Baxter produces pharmaceuticals, including anaesthetics such as Suprane (Desflurane, USP) and Forane (Isoflurane, USP)
and aims at expand its market share in the Middle East, in particular with regard to Desflurane.
AQAI configured simulators, the equipment landscape, and
sophisticated scenarios which represent the application context in a
realistic manner. The technology encompasses heating, vaporization,
as well as real washing in and out of the anaesthetic. Barriers
which needed to be overcome included climate challenges: the boiling
point of Desflurane is approximately 23C, a temperature that is
frequently exceeded in the Middle East.
This simulation configuration was implemented at the University
Hospital in Riyadh, Saudi Arabia. AQAI has made similar
installations in the UK, in Russia, Egypt, and South Africa, where
they provided significant support for product roll-out and today
serve in routine further education in anaesthetics application.
First simulation course a success
In mid May 2012 Baxter organized the first simulation-based
training for Desflurane in Saudi Arabia. “We are highly satisfied
with how the scenarios turned out. They worked without problems and
in accordance with our expectations, and they produced the desired
know-how for participants”, said Ala Asi who is in charge of Baxter
“We will focus even more on the application of Suprane in the
future; and we plan to develop scenarios which help communicate in
detail the differences between handling Suprane in comparison with
Sevoflurane [a competitive product] and Isoflurane”.
Baxter will collaborate with AQAI on these projects. The next
simulation-based training for anaesthetics in Riyadh is scheduled
for late September.
“Our innovative approach supports manufacturers and care
providers in ensuring safe application of new products by the staff
— without putting life, and quality of life, of patients at risk”,
underlines Prof. Dr. med. Wolfgang Heinrichs, anesthetist and
Director of the AQAI Simulation Center. According to the expert, the
potentials for the use of simulation in the context of the roll-out
of many other pharmaceuticals and medtech products are huge.